A. Argiris

发表

M. Karamouzis, R. Ferris, A. Argiris, 2008, The Lancet.

Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics.

A. Docea, A. Tsatsakis, A. Argiris, 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

E. Vokes, A. Argiris, D. Haraf, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Small cell lung cancer and other thoracic malignancies

M. Nishimura, Y. Hosomi, M. Shibuya, 2012 .

Characterization of human papillomavirus antibodies in individuals with head and neck cancer.

R. Ferris, M. Pawlita, A. Argiris, 2016, Cancer epidemiology.

Deferring Planned Neck Dissection Following Chemoradiation for Stage IV Head and Neck Cancer: The Utility of PET‐CT

D. Heron, R. Ferris, A. Argiris, 2007, The Laryngoscope.

Evaluating the supportive care costs of severe radiochemotherapy‐induced mucositis and pharyngitis

A. Argiris, C. Bennett, M. Agulnik, 2008, Cancer.

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

A. Argiris, M. Avram, V. Kut, 2006, Investigational New Drugs.

A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG).

A. Argiris, J. Gilbert, B. Burtness, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

A. Egloff, J. Grandis, A. Argiris, 2012, Investigational New Drugs.

Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.

R. Weichselbaum, E. Vokes, A. Argiris, 2005, International journal of radiation oncology, biology, physics.

A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.

A. Argiris, M. Liptay, M. Kies, 2004, Lung cancer.

Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303

A. Egloff, R. Seethala, Lin Wang, 2014, Clinical Cancer Research.

Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

N. Simone, Minyoung Jang, Seungwon Kim, 2011, Clinical Cancer Research.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Non-Small Cell Lung Cancer: A SEER Cohort Study

A. Argiris, R. Mehta, D. Lenzner, 2012, Annals of surgical oncology.

Prognosis Tumor Epidermal Growth Factor Receptor and EGFRPY 1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

G. Mills, J. Siegfried, A. Egloff, 2012 .

Combined Targeting of EGFR and Angiogenesis in Aerodigestive Carcinomas

M. Karamouzis, A. Argiris, 2009 .

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

D. Heron, J. Johnson, J. Grandis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC).

A. Argiris, C. Belani, D. Friedland, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Staging and Monitoring of Small Cell Lung Cancer Using [18F]Fluoro-2-deoxy-D-glucose-Positron Emission Tomography (FDG-PET)

William Spies, Athanassios Argiris, A. Argiris, 2007, American journal of clinical oncology.

Staging and clinical prognostic factors for small-cell lung cancer.

A. Argiris, J. Murren, Athanassios Argiris, 2001, Cancer journal.

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

B. Leiby, A. Argiris, A. Flanders, 2020, Frontiers in Oncology.

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck

A. Argiris, B. Burtness, R. Axelrod, 2011, Cancer.

Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.

D. Heron, M. Karamouzis, J. Johnson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.

J. Manola, A. Argiris, B. Burtness, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib

A. Argiris, J. Coon, V. Villaflor, 2008, Clinical Cancer Research.

CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

R. Ferris, A. Argiris, T. Whiteside, 2015, Cancer research.

Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.

B. Schilling, A. Argiris, T. Whiteside, 2012, Journal of immunological methods.

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer

M. Socinski, J. Siegfried, T. Burns, 2017, Cancer.

Pemetrexed: a novel antifolate agent enters clinical practice

A. Argiris, J. Patel, V. Kut, 2004, Expert review of anticancer therapy.

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.

A. Argiris, N. Mittal, 2004, Lung cancer.

Chemotherapy in the Management of Malignant Tumors of Salivary Gland Origin

A. Argiris, S. Laurie, 2007 .

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.

A. Chakravarti, A. Argiris, J. Gilbert, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab

R. Seethala, J. Grandis, A. Argiris, 2011, Clinical Cancer Research.

Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients

R. Ferris, A. Argiris, J. Bauman, 2017, Cancer Immunology Research.

Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.

A. Argiris, J. Curry, D. Cognetti, 2022, Cancer treatment reviews.

Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

F. Zhu, A. Egloff, Lin Wang, 2013 .

Update on chemoradiotherapy for head and neck cancer

A. Argiris, 2002, Current opinion in oncology.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.

A. Argiris, A. Adjei, J. Murren, 1999, Seminars in oncology.

Splenic and renal infarctions complicating atrial fibrillation.

A. Argiris, 1997, The Mount Sinai journal of medicine, New York.

Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.

A. Jimeno, A. Argiris, L. Wirth, 2014 .

Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck

E. Vokes, A. Argiris, D. Haraf, 2004, Clinical Cancer Research.

Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer

D. Zelterman, A. Argiris, B. Burtness, 2002, Cancer biology & therapy.

Induction chemotherapy for resectable non-small-cell lung cancer.

A. Argiris, M. Blum, J. Patel, 2004, Oncology.

Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922).

S. Ramalingam, A. Argiris, M. Egorin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract C70: A phase 2 study of intravenous administration of REOLYSIN® (reovirus type 3 dearing) in combination with paclitaxel (P) and carboplatin (C) in patients with squamous cell carcinoma of the lung.

A. Argiris, M. Mita, A. Mita, 2013 .

Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.

E. Vokes, A. Argiris, D. Haraf, 2003, The oncologist.

Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: The University of Pittsburgh experience

D. Heron, R. Carrau, J. Grandis, 2009, The Laryngoscope.

High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.

A. Argiris, D. Cooper, S. Seropian, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors in patients with high‐risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy

D. Heron, J. Grandis, R. Ferris, 2011, Head & neck.

Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers

A. Argiris, J. Lefebvre, 2019, Front. Oncol..

A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.

J. Luketich, D. Liggitt, S. Ramalingam, 2010, Human gene therapy.

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.

M. Maitland, D. Gandara, S. Ramalingam, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy induced soft tissue sarcoma: an unusual case of a dermatofibrosarcoma protuberans.

A. Argiris, K. Aroni, C. Dardoufas, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.

M. Socinski, J. Siegfried, A. Argiris, 2013, Anticancer research.

T2 relaxation times of irradiated vertebral bone marrow in patients with seminoma.

A. Argiris, L. Vlahos, T. Maris, 1997, Magnetic resonance imaging.

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

J. Netterville, B. Leiby, A. Argiris, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long‐Term Results of a Phase III Randomized Trial of Postoperative Radiotherapy With or Without Carboplatin in Patients With High‐Risk Head and Neck Cancer

D. Heron, M. Karamouzis, J. Grandis, 2008, The Laryngoscope.

A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores

D. Cella, S. Yount, R. Bode, 2007, Quality of Life Research.

Nasopharyngeal Cancer in Non-Endemic Areas: Impact of Treatment Intensity within a Large Retrospective Multicenter Cohort

A. Argiris, A. Trama, P. Franco, 2021, SSRN Electronic Journal.

Prognostic factors and long‐term survivorship in patients with recurrent or metastatic carcinoma of the head and neck

A. Argiris, Yi Li, A. Forastiere, 2004, Cancer.

A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).

M. Biel, A. Gillenwater, A. Argiris, 2019, Journal of Clinical Oncology.

Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).

D. Heron, J. Luketich, S. Dacic, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

R. Govindan, S. Ou, Weiwei Tan, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abnormalities of serum amylase and lipase in HIV-positive patients

A. Argiris, D. Mildvan, U. Mathur-Wagh, 1999, American Journal of Gastroenterology.

Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review.

A. Rademaker, E. Vokes, A. Argiris, 2003, International journal of radiation oncology, biology, physics.

Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers.

J. Flickinger, D. Heron, R. Ferris, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Planned Post‐Chemoradiation Neck Dissection: Significance of Radiation Dose

E. Vokes, A. Argiris, D. Huo, 2006, The Laryngoscope.

Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer

E. Vokes, A. Argiris, D. Haraf, 2004, Head & neck.

Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners

A. Baum, M. Dew, R. Ferris, 2015, Head & neck.

Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

S. Ramalingam, A. Argiris, M. Egorin, 2007, Clinical Cancer Research.

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

R. Ferris, A. Argiris, R. Haddad, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

G. Mills, J. Siegfried, A. Egloff, 2012, Clinical Cancer Research.

Esthesioneuroblastoma: The Northwestern University Experience

A. Argiris, J. Dutra, P. Tseke, 2003, The Laryngoscope.

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.

M. Karamouzis, J. Grandis, A. Argiris, 2007, JAMA.

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

L. Butterfield, R. Ferris, A. Argiris, 2014, Clinical Cancer Research.

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

D. Hayes, H. Lenz, E. Vokes, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy.

D. Heron, J. Johnson, J. Grandis, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

R. Ferris, A. Argiris, U. Müller-Richter, 2021, Annals of Oncology.

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma

A. Argiris, V. Bar-ad, B. Lu, 2019, Front. Oncol..

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

K. Harrington, A. Argiris, L. Licitra, 2017, Front. Oncol..

Epidemiology, staging, and screening of head and neck cancer.

A. Argiris, C. Eng, 2003, Cancer treatment and research.

Phase II Trial of 9-Aminocamptothecin as a 72-h Infusion in Cutaneous T-Cell Lymphoma

S. Arbuck, A. Argiris, T. Kuzel, 2001, Investigational New Drugs.

Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.

A. Argiris, I. Vathiotis, J. Johnson, 2021, Cancer treatment reviews.

Update on the role of EGFR inhibitors in cancer therapeutics.

M. Karamouzis, A. Argiris, 2007, Cancer treatment and research.

A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study.

C. Van Waes, A. Argiris, M. Goldwasser, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer

J. Dancey, E. Vokes, A. Argiris, 2006, Cancer biology & therapy.

Targeting Angiogenesis from Premalignancy to Metastases

J. Grandis, A. Argiris, 2009, Cancer Prevention Research.

Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents.

A. Argiris, J. Murren, 2001, Cancer journal.

Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.

A. Argiris, J. Gilbert, 2006, Clinical advances in hematology & oncology : H&O.

The impact of health insurance status on the survival of patients with head and neck cancer

Scott M Langevin, J. Grandis, A. Argiris, 2010, Cancer.

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

S. Dacic, A. Argiris, C. Belani, 2010, Clinical Cancer Research.

Cancer Therapy : Clinical Phase II Study of Everolimus ( RAD 001 ) in Previously Treated Small Cell Lung Cancer

S. Dacic, A. Argiris, C. Belani, 2010 .

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

A. Chen, D. Gandara, T. Owonikoko, 2019, Cancer Chemotherapy and Pharmacology.

A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.

A. Chen, T. Owonikoko, S. Ramalingam, 2012 .

Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.

R. Seethala, Lin Wang, J. Grandis, 2011, Oral oncology.

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).

S. Gettinger, K. Kelly, D. Gandara, 2021, Clinical lung cancer.

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)

S. Ramalingam, A. Argiris, J. Schiller, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II randomized trial of carboplatin , paclitaxel , bevacizumab with or without cixutumumab ( IMCA 12 ) in patients with advanced non-squamous , non-small-cell lung cancer : a trial of the ECOG-ACRIN Cancer Research Group ( E 3508 )

S. Ramalingam, A. Argiris, J. Schiller, 2017 .

Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives

D. Heron, J. Grandis, Seungwon Kim, 2018, Cancer.

Current and Emerging Roles of Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small Cell Lung Cancer

M. Karamouzis, T. Owonikoko, A. Argiris, 2010 .

XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

M. Romkes, R. Seethala, Lin Wang, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

M. Romkes, R. Seethala, Lin Wang, 2011 .

Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

J. Grandis, R. Ferris, A. Argiris, 2012, Oral oncology.

Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.

B. Pasche, A. Argiris, J. Patel, 2004, Critical reviews in oncology/hematology.

Radiotherapy effects on vertebral bone marrow: easily recognizable changes in T2 relaxation times.

A. Argiris, A. Gouliamos, T. Maris, 1996, Magnetic resonance imaging.

Cancer Therapy : Clinical Phase I Dendritic Cell p 53 Peptide Vaccine for Head and Neck Cancer

Eld, R. Ferris, A. Argiris, 2014 .

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

S. Zhong, M. Karamouzis, M. Romkes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.

D. Heron, R. Seethala, Lin Wang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.

G. Mills, J. Mountz, A. Egloff, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET scan assessment of chemotherapy response in metastatic paraganglioma.

A. Argiris, S. Spies, A. Mellott, 2003, American journal of clinical oncology.

Revisiting induction chemotherapy for head and neck cancer.

A. Argiris, D. Pichardo, P. Jayaram, 2005, Oncology.

Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy

E. Vokes, A. Argiris, D. Haraf, 2004, Clinical Cancer Research.

Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

Athanassios Argiris, A. Argiris, S. Whalen, 2004, Clinical Cancer Research.

Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.

A. Argiris, B. Murphy, C. Langer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New and Promising Targeted Therapies in First and Second-Line Settings

Paolo Bossi, Dylan F. Roden, Jennifer Johnson, 2021, Critical Issues in Head and Neck Oncology.

Subdividing NSCLC: reflections on the past, present, and future of lung cancer therapy.

S. Dacic, A. Argiris, S. Gadgeel, 2009, Oncology.

A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

A. Jimeno, A. Argiris, L. Wirth, 2016, Cancer.

Angiogenesis and Anti-angiogenic Therapy in Head and Neck Cancer

A. Argiris, J. Johnson, L. Wilde, 2018 .

Targeting growth factors and angiogenesis; using small molecules in malignancy

H. Rugo, A. Argiris, H. Wanebo, 2006, Cancer and Metastasis Reviews.

Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.

N. Senzer, J. Nemunaitis, R. Ferris, 2014 .

Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer

A. Argiris, B. Swendseid, J. Curry, 2021, Frontiers in Oncology.

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

J. Grandis, P. Harari, A. Argiris, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Postoperative treatment for head and neck cancer: the emerging role of EGFR-targeted therapy

A. Argiris, A. Rapidis, 2016 .

Empowering induction therapy for locally advanced head and neck cancer.

M. Karamouzis, A. Argiris, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.

J. Mountz, D. Heron, M. Karamouzis, 2009, International journal of radiation oncology, biology, physics.

Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era

R. de Bree, A. Mäkitie, A. Argiris, 2022, Cancers.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

J. Grandis, A. Argiris, J. Bauman, 2016, Head & neck.

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Simion I. Chiosea, J. Siegfried, Lin Wang, 2014, Clinical Cancer Research.

A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer

M. Karamouzis, A. Argiris, S. Carty, 2008, Investigational New Drugs.

Unilateral breast oedema as a manifestation of congestive heart failure.

A. Argiris, D. Gould, 1998, Journal of Internal Medicine.

The Contribution of Chemotherapy

M. Karamouzis, A. Argiris, M. Gibson, 2009 .

Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG‐ACRIN Cancer Research Group (E1302)

D. Cella, A. Argiris, A. Forastiere, 2020, Cancer medicine.

The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation Therapy

D. Heron, Yong Yang, J. Grandis, 2011, American journal of clinical oncology.

Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable squamous cell carcinoma of the head and neck (SCCHN).

B. Leiby, A. Argiris, U. Rodeck, 2020 .

Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer.

B. Leiby, A. Argiris, V. Bar-ad, 2020 .

Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

D. Heron, J. Johnson, R. Ferris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Current status and future directions in induction chemotherapy for head and neck cancer.

A. Argiris, 2013, Critical reviews in oncology/hematology.

Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer.

D. Heron, R. Ferris, A. Argiris, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

An update on angiogenesis targeting in head and neck squamous cell carcinoma

A. Argiris, J. Johnson, I. Micaily, 2020, Cancers of the Head & Neck.

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.

A. Egloff, A. Argiris, R. Mehra, 2014 .

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.

A. Egloff, Lin Wang, L. Wang, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance Therapy for Advanced-Non Small Cell Lung Cancer

A. Argiris, A. Tarhini, 2010 .

Progress in the therapy of small cell lung cancer.

A. Argiris, J. Murren, M. Simon, 2004, Critical reviews in oncology/hematology.

Molecular strategies and 111in-labelled somatostatin analogues in defining the management of neuroendocrine tumour disease: a new paradigm for surgical management.

T. Hinoue, A. Argiris, M. Kidd, 2003, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck

A. Argiris, P. Fu, M. Yao, 2015, Head & neck.

Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.

B. Leiby, A. Argiris, R. Zinner, 2020 .

Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia.

A. Argiris, A. Gidron, Nicolas Dimov, 2006, American Journal of Clinical Oncology.

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

D. Heron, J. Luketich, S. Dacic, 2013, Lung cancer.

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.

J. Kolesar, A. Argiris, J. Gilbert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

D. Gandara, F. Shepherd, S. Ramalingam, 2011, Clinical lung cancer.

Targeting angiogenesis in head and neck cancer.

A. Argiris, A. Psyrri, M. Vassilakopoulou, 2015, Oral oncology.

Revisiting induction chemotherapy for head and neck cancer. References and reviews.

A. Argiris, D. Pichardo, P. Jayaram, 2005, Oncology.

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer

Ashley L. Buchanan, J. Kolesar, A. Argiris, 2009, Cancer.

CD8+ and FoxP3+ T‐Cell Cellular Density and Spatial Distribution After Programmed Death‐Ligand 1 Check Point Inhibition

A. Argiris, U. Martinez-outschoorn, J. Curry, 2022, The Laryngoscope.

A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non–Small-Cell Lung Cancer

L. Bloss, C. Obasaju, E. Hahn, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Induction chemotherapy for head and neck cancer: will history repeat itself?

A. Argiris, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

EGFR inhibition for recurrent or metastatic HNSCC.

A. Argiris, 2015, The Lancet. Oncology.

Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG)

A. Argiris, M. Goldwasser, R. Axelrod, 2005 .

Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary.

E. Vokes, A. Argiris, D. Haraf, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of dasatanib (BMS 354825) in recurrent or metastatic ckit-expressing adenoid cystic (ACC) and non-ACC malignant salivary glands tumors (MSGT).

John D. Roberts, D. Hayes, H. Lenz, 2013 .

Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story

T. Hensing, J. Kolesar, A. Argiris, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I and Pharmacokinetic Study ofVorinostat , AHistone Deacetylase Inhibitor , in Combinationwith Carboplatin and Paclitaxel forAdvanced Solid Malignancies

S. Ramalingam, A. Argiris, M. Egorin, 2007 .

A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial

S. Groshen, D. Gandara, M. Edelman, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

p53‐Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study

J. Michalek, R. Elledge, G. Swanson, 2016, Molecular Oncology.

Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal Cancer

A. Darzi, G. Hanna, H. Ashrafian, 2017, Annals of surgical oncology.

Phase III randomized trial of postoperative radiotherapy (RT) with or without carboplatin (Cb) in patients (pts) with head and neck squamous cell carcinoma (HNSCC)

D. Heron, M. Karamouzis, A. Argiris, 2007 .

Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort.

A. Argiris, I. Garassino, A. Trama, 2021, European journal of cancer.

Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer

R. Weichselbaum, E. Vokes, A. Argiris, 2003 .

632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301

J. Manola, A. Argiris, B. Burtness, 2006 .

A randomized phase II study of BMS-247550 (ixabepilone) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck.

A. Argiris, M. Goldwasser, B. Burtness, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN).

D. Heron, J. Grandis, R. Ferris, 2010 .

Can current treatments for advanced non-small-cell lung cancer be improved?

A. Argiris, J. Schiller, 2004, JAMA.

Pemetrexed in head and neck cancer: a systematic review.

C. Obasaju, A. Argiris, A. Hossain, 2013, Oral oncology.

A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer

C. Rudin, R. Govindan, A. Argiris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety of nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

A. Argiris, U. Rodeck, R. Zinner, 2019, Journal of Clinical Oncology.

Cetuximab-induced aseptic meningitis.

A. Argiris, M. Gibson, T. Feinstein, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

672P Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results on efficacy and correlative analysis

A. Argiris, R. Axelrod, D. Cognetti, 2022, Annals of Oncology.

Phase II trial of R-(-)-gossypol acetic acid (NSC 726190, AT-101) in patients with recurrent extensive stage small cell lung cancer (ES-SCLC).

R. Govindan, A. Argiris, M. Millward, 2010 .

Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863).

M. Maitland, D. Gandara, S. Ramalingam, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib.

A. Argiris, J. Coon, V. Villaflor, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Faculty Opinions recommendation of Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

M. Karamouzis, A. Argiris, 2009 .

A phase II randomized trial of anastrozole (A) and fulvestrant (F) as consolidation therapy in postmenopausal women with advanced non-small cell lung cancer who have received first-line platinum-based chemotherapy with or without bevacizumab.

A. Argiris, S. Land, A. Tarhini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-612 Gefitinib (Iressa, ZD1839) is active as first-line, compassionate use therapy in patients with advanced non-small cell lung cancer (NSCLC)

A. Argiris, G. Masters, N. Mittal, 2003 .

Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

S. Ramalingam, A. Argiris, M. Egorin, 2007, Clinical Cancer Research.

CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

R. Ferris, A. Argiris, T. Whiteside, 2015, Cancer research.

Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.

R. Seethala, Lin Wang, J. Grandis, 2011, Oral oncology.

Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN).

D. Heron, J. Grandis, R. Ferris, 2010 .

Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis

Helen X. Chen, J. Grandis, Seungwon Kim, 2008 .

Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Non-Small Cell Lung Cancer: A SEER Cohort Study

A. Argiris, R. Mehta, D. Lenzner, 2012, Annals of Surgical Oncology.

Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial

M. Karamouzis, A. Argiris, L. Raez, 2008 .

Phase I/II Study to Assess the Safety, Pharmacokinetics (PK) and Efficacy of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Carboplatin/Etoposide in Patients with Solid Tumors Including Small-Cell Lung Cancer (SCLC)

A. Argiris, J. Bendell, A. Mita, 2012 .

Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers.

J. Flickinger, D. Heron, R. Ferris, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

J. Grandis, A. Argiris, J. Bauman, 2016, Head & neck.

Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab

R. Seethala, J. Grandis, A. Argiris, 2011, Clinical Cancer Research.

Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients

R. Caprioli, D. Carbone, C. Chung, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Faculty Opinions recommendation of E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

A. Argiris, J. Johnson, 2017 .

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck

A. Argiris, M. Mahoney, J. Curry, 2023, Journal for ImmunoTherapy of Cancer.

In-field toxicity analysis of a phase I clinical trial of nivolumab and ipilimumab with definitive radiation therapy in locally advanced squamous cell carcinoma of the head and neck: In-Field toxicity of immune-RT in LA-SCCHN.

A. Argiris, V. Bar-ad, R. Axelrod, 2023, International journal of radiation oncology, biology, physics.

Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC)

D. Heron, M. Karamouzis, J. Grandis, 2007 .

Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN).

A. Argiris, C. Hoppel, M. Cooney, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

S. Dacic, A. Argiris, C. Belani, 2010, Clinical Cancer Research.

Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report.

J. Grandis, A. Argiris, F. Worden, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis

M. Karamouzis, A. Argiris, B. Branstetter, 2007 .

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

E. Vokes, A. Argiris, D. Haraf, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer

Ashley L. Buchanan, J. Kolesar, A. Argiris, 2009, Cancer.

p53‐Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study

J. Michalek, R. Elledge, G. Swanson, 2016, Molecular oncology.